CA
DYN icon

Continuum Advisory’s Dyne Therapeutics DYN Stock Holding History

Continuum Advisory’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95K Buy
+88
New +$1.64K ﹤0.01% 1737

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Continuum Advisory's DYN Position: Q2 2026 in Review

Continuum Advisory opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 88 shares worth $1.95K. The stake represents ﹤0.01% of the portfolio and ranks #1737 among its holdings.

246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Continuum Advisory held 88 shares of Dyne Therapeutics worth $1.95K as of Q2 2026.
  • Dyne Therapeutics was a new Continuum Advisory position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1737 holding.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.